In short
Radspherin, a novel drug containing Radium-224 adsorbed in calcium carbonate microparticles, is currently being studied in clinical trials for the treatment of peritoneal cancer. These trials aim to evaluate the efficacy and safety of Radspherin as an intraperitoneal α-emitting radionuclide therapy in patients with peritoneal metastases from colorectal cancer and advanced ovarian, fallopian tube, or primary peritoneal cancer. The studies focus on patients undergoing various treatments, including cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and neoadjuvant chemotherapy.
What is Radspherin?
Radspherin is an innovative medical treatment currently being studied for patients with certain types of cancer that have spread to the lining of the abdominal cavity, a condition known as peritoneal carcinomatosis. It is classified as an intraperitoneal α-emitting radionuclide therapy, which means it uses radioactive particles to target cancer cells within the abdominal cavity.
How Does Radspherin Work?
Radspherin contains a radioactive substance called radium-224 that is attached to tiny particles of calcium carbonate. When injected into the abdominal cavity, these particles can deliver targeted radiation to cancer cells. The radiation emitted by radium-224 is in the form of alpha particles, which have a very short range but high energy, potentially allowing for effective treatment of cancer cells while minimizing damage to surrounding healthy tissue.
What Conditions Does Radspherin Treat?
Radspherin is being investigated for the treatment of peritoneal carcinomatosis arising from different types of cancer, including:
- Colorectal cancer that has spread to the peritoneum (the lining of the abdominal cavity)
- Advanced ovarian cancer, including high-grade serous or high-grade endometrioid epithelial ovarian cancer
- Fallopian tube cancer with peritoneal metastasis
- Primary peritoneal cancer
Ongoing Clinical Trials
Radspherin is currently being studied in Phase 2 clinical trials. These trials are designed to evaluate how well the treatment works and how safe it is compared to standard treatments. Two main studies are ongoing:
- A study for patients with peritoneal carcinomatosis from colorectal cancer who have undergone cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
- A study for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who are scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Potential Benefits
The clinical trials aim to determine if Radspherin can provide benefits such as:
- Improved progression-free survival (the time without cancer growth or spread)
- Increased overall survival
- Better quality of life for patients
- Delayed need for subsequent cancer treatments
Eligibility for Treatment
Eligibility for Radspherin treatment in these clinical trials typically includes:
- Confirmed diagnosis of the specific cancer types being studied
- Presence of peritoneal metastases that can be surgically removed
- Adequate organ function (kidney, liver, and bone marrow)
- Good overall health status (ECOG Performance Status of 0 to 2)
- Age 18 years or older
Patients with certain conditions may not be eligible, such as those with active infections, other recent cancers, or specific genetic mutations (in the case of the ovarian cancer study).
Administration and Dosage
Radspherin is administered as an intraperitoneal injection, which means it is injected directly into the abdominal cavity. The maximum dose being studied is 7 MBq (megabecquerels, a unit of radioactivity). The treatment is typically given as a single dose, although the exact timing and integration with other treatments may vary depending on the specific clinical trial.
Safety and Side Effects
As Radspherin is still in clinical trials, its full safety profile is not yet established. The ongoing studies are carefully monitoring for any side effects or complications. Patients receiving Radspherin will be closely observed for:
- Changes in blood cell counts
- Liver and kidney function
- Surgical complications
- Any other adverse events
Due to the radioactive nature of the treatment, special precautions are necessary, including the use of effective contraception for both male and female patients for a period after treatment.
Conclusion
Radspherin represents a promising new approach to treating peritoneal carcinomatosis from various types of cancer. By delivering targeted radiation directly to cancer cells within the abdominal cavity, it may offer a new option for patients who have limited treatment choices. However, as it is still in clinical trials, more research is needed to fully understand its effectiveness and safety profile. Patients interested in this treatment should discuss with their oncologist whether participating in a clinical trial might be appropriate for their specific situation.